Apixaban Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition
Apixaban Price Trend, Index and Forecast
Track the latest insights on apixaban price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.
Apixaban Prices Outlook Q2 2026
- USA: USD 51,953/MT
- China: USD 24,078/MT
- Germany: USD 58,454/MT
- India: USD 30,499/MT
- Korea: USD 43,993/MT
Apixaban Price Chart
Get real-time access to monthly/quaterly/yearly prices, Request Sample
During the second quarter of 2026, the apixaban prices in the USA reached 51,953 USD/MT in June. Prices firmed as demand for the anticoagulant active pharmaceutical ingredient remained strong among branded and generic drug manufacturers producing therapies for atrial fibrillation and venous thromboembolism. Tighter availability of high purity batches meeting stringent regulatory specifications supported firmer offers from domestic producers. Elevated costs for specialized synthesis intermediates and solvent recovery processes added further pressure on manufacturing economics.
During the second quarter of 2026, the apixaban prices in China reached 24,078 USD/MT in June. Prices moved upward as domestic active pharmaceutical ingredient manufacturers expanded output to meet rising export orders from generic drug formulators across Asia and Europe. Higher costs for key starting materials and intermediates used in the multi-step synthesis route added pressure on production economics. Steady demand from domestic cardiovascular therapy programs and hospital procurement channels supported consistent offtake during the quarter.
During the second quarter of 2026, the apixaban prices in Germany reached 58,454 USD/MT in June. Prices increased as European formulators maintained steady procurement of pharmacopeial grade apixaban to support ongoing generic and branded tablet production. Stringent European quality and traceability requirements limited the number of approved suppliers, keeping the market relatively tight. Rising energy and labor costs at specialized fine chemical manufacturing sites added further pressure to delivered values.
During the second quarter of 2026, the apixaban prices in India reached 30,499 USD/MT in June. Prices rose as domestic bulk drug manufacturers ramped up production to serve strong export demand from regulated markets in North America and Europe. Higher costs of key starting materials and reagents used in the synthesis process added to overall production expenses. Consistent demand from domestic generic formulators supplying cardiovascular therapy programs kept procurement active across the quarter.
During the second quarter of 2026, the apixaban prices in Korea reached 43,993 USD/MT in June. Prices advanced as domestic fine chemical producers maintained firm offers amid steady demand from regional generic drug manufacturers. Rising costs for specialized reagents and catalysts used during synthesis contributed to the higher price trend. Consistent demand from cardiovascular treatment programs across East Asia supported stable offtake throughout the quarter.
Apixaban Prices Outlook Q2 2025
- USA: USD 44,617/MT
- China: USD 24,295/MT
- Germany: USD 55,269/MT
- India: USD 30,369/MT
- Korea: USD 43,946/MT
During the second quarter of 2025, apixaban prices in the USA reached 44,617 USD/MT in June. Apixaban prices in the United States followed a steady upward trend, primarily driven by consistent demand for cardiovascular and stroke prevention therapies. The increase was supported by stable domestic consumption, incremental rises in API production costs, and regulatory compliance expenses. While the presence of generics helped temper sharp fluctuations, overall pricing remained firm due to steady supply chain operations and healthcare utilization patterns. The quarter reflected a controlled rise in prices aligned with input costs and therapeutic demand.
During the second quarter of 2025, apixaban prices in China reached 24,295 USD/MT in June. Apixaban prices in China continued to grow, building on the strong sales and market expansion seen in prior years. Ongoing demand linked to cardiovascular treatments reinforced robust API procurement, while limited competition among major domestic manufacturers sustained pricing strength. Supply remained consistent, though manufacturers closely monitored fermentation input costs, which added slight upward pressure.
During the second quarter of 2025, apixaban prices in Germany reached 55,269 USD/MT in June. Apixaban prices remained relatively firm, reflecting stable demand from the country’s advanced healthcare system and tight patent-related supply controls. Industrial pricing is influenced by fermentation-based API production costs and ongoing delays in the generic pipeline, which help sustain pricing resilience. Distribution through hospital and retail pharmacy channels exhibited consistent procurement patterns, minimizing volatility.
During the second quarter of 2025, apixaban prices in India reached 30,369 USD/MT in June. Apixaban price in India exhibited moderate firmness, supported by consistent demand from hospitals and specialty clinics focused on cardiovascular treatments. Domestic manufacturers and importers—primarily sourcing APIs from local and Chinese producers—ensured a stable supply environment. Currency fluctuations and elevated formulation costs contributed to slight upward pricing pressure. Overall, the pricing trend reflected a balanced mix of supply-side assurance and steady downstream demand.
During the second quarter of 2025, apixaban prices in Korea reached 43,946 USD/MT in June. Apixaban prices remained stable to slightly firm, underpinned by consistent demand from the country’s well-established healthcare infrastructure. While early domestic generic activity introduced modest competitive pressure, reliance on imported APIs and recent approvals for expanded therapeutic indications helped sustain price levels. The market exhibited a balanced trend, shaped by steady healthcare utilization and dependable supply chains, reinforcing a resilient pricing environment throughout the quarter.
Regional Coverage
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing apixaban prices.
Europe Apixaban Price Trend
Q2 2026:
The apixaban price index in Europe moved upward during the quarter as steady demand for the anticoagulant active pharmaceutical ingredient continued across branded and generic tablet manufacturers. Germany remained the key regional reference point, with prices firming on tighter availability of pharmacopeial grade material meeting strict European quality and traceability standards. Rising energy and labor costs at specialized fine chemical production sites added further pressure to delivered values across the region. Import dependence on select global suppliers for certain synthesis intermediates also supported the firmer pricing trend. Demand from hospital pharmacies and outpatient anticoagulation therapy programs remained consistent throughout the quarter, reflecting the growing prevalence of atrial fibrillation and venous thromboembolism among aging populations.
Q2 2025:
Apixaban prices in Europe remained relatively stable, with modest fluctuations driven by changes in manufacturing costs and the availability of active pharmaceutical ingredients (APIs). Demand across key markets, such as Germany, France, and Italy, remained steady due to the widespread use of anticoagulant therapies. Supply chains across the region were largely uninterrupted, supporting consistent availability. Overall, the pricing environment reflected balanced market conditions aligned with steady therapeutic demand and regional production dynamics.
This analysis can be extended to include detailed apixaban price information for a comprehensive list of countries.
| Region | Countries Covered |
|---|---|
| Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
North American apixaban Price Trend
Q2 2026:
The apixaban price index in North America trended higher during the quarter as sustained demand from branded and generic anticoagulant drug manufacturers supported firmer offers. The United States remained the dominant regional market, with prices rising on tighter availability of high purity active pharmaceutical ingredient batches meeting stringent regulatory specifications. Elevated costs for specialized synthesis intermediates and solvent recovery processes added continued pressure on manufacturing economics throughout the quarter. Growth in oral anticoagulant prescriptions among an aging population kept procurement active among formulation companies serving both hospital and retail pharmacy channels. Strict quality compliance requirements under regulatory oversight limited the pool of qualified suppliers capable of meeting incremental demand quickly.
Q2 2025:
In North America, apixaban prices exhibited mild fluctuations, primarily influenced by variable raw material and manufacturing costs. Steady demand from the healthcare sector supported price stability across the region. While regulatory compliance and pharmaceutical manufacturing standards continued to drive operational expenses, the presence of both branded and generic versions helped moderate any significant price shifts. Supply chains remained largely undisrupted, ensuring consistent market availability.
Specific apixaban historical data within the United States and Canada can also be provided.
| Region | Countries Covered |
|---|---|
| North America | United States and Canada |
Middle East and African apixaban Price Trend
Q2 2026:
The study includes apixaban price trends across the Middle East and Africa, taking into consideration variables that have a direct impact on market prices, such as regional healthcare expenditure, pharmaceutical import dependency, and evolving regulatory frameworks.
Q2 2025:
The report explores the apixaban trends and apixaban price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
In addition to region-wise data, information on apixaban prices for countries can also be provided.
| Region | Countries Covered |
|---|---|
| Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Asia Pacific Apixaban Price Trend
Q2 2026:
Apixaban prices in Asia Pacific moved upward during the quarter as active pharmaceutical ingredient manufacturers across China, India, and Korea responded to strong export and domestic demand. China experienced firmer offers as bulk drug producers expanded output to meet rising orders from generic formulators across Asia and Europe, while higher costs for key starting materials added to production expenses. India recorded a similar upward trend as manufacturers ramped up capacity utilization to serve regulated export markets in North America and Europe alongside steady domestic generic demand. Korea saw prices advance as fine chemical producers maintained firm offers amid limited spare production capacity and rising costs for specialized reagents and catalysts. Demand from cardiovascular therapy programs across the region remained resilient, supported by growing prevalence of atrial fibrillation and thromboembolic disorders among aging populations.
Q2 2025:
In the Asia-Pacific region, apixaban prices remained relatively stable, with minor fluctuations influenced by active pharmaceutical ingredient (API) costs and regional production dynamics. Key manufacturing hubs, such as India and China, maintained consistent output, supported by steady demand from both domestic and export markets. However, robust supply chains and growing adoption in cardiovascular therapies helped sustain balanced market conditions. Overall, prices reflected stable demand, aligned with trends in raw materials and manufacturing efficiencies across the region.
This apixaban price analysis can be expanded to include a comprehensive list of countries within the region.
| Region | Countries Covered |
|---|---|
| Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Latin American apixaban Price Trend
Q2 2026:
The analysis of apixaban prices in Latin America provides a detailed overview, reflecting the unique market dynamics in the region influenced by healthcare regulatory frameworks, pharmaceutical import reliance, and trade policies.
Q2 2025:
Latin America's apixaban market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in apixaban prices. Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting the region's ability to meet international demand consistently. Moreover, apixaban index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing apixaban pricing trends in this region.
This comprehensive review can be extended to include specific countries within the region.
| Region | Countries Covered |
|---|---|
| Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
Apixaban Pricing Report, Market Analysis, and News
IMARC's latest publication, “Apixaban Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition,” presents a detailed examination of the apixaban market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of apixaban at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents detailed apixaban prices trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting apixaban pricing, such as the dynamics of supply and demand, geopolitical influences, and sector specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.
Apixaban Industry Analysis
The global apixaban market size reached USD 12.55 Billion in 2025. By 2034, IMARC Group expects the market to reach USD 21.79 Billion, at a projected CAGR of 6.32% during 2026-2034. Market growth is being driven by the rising global prevalence of atrial fibrillation and venous thromboembolism that is increasing demand for effective oral anticoagulant therapies, the expanding geriatric population that is more susceptible to cardiovascular and thromboembolic disorders requiring long term anticoagulation management, and the growing availability of generic apixaban formulations following patent expirations that is broadening patient access across both developed and emerging healthcare markets.
Latest News and Developments:
- November 2023: THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM) and the AMERICAN HEART ASSOCIATION published a study in November 2023 that found the widely available blood thinner apixaban significantly reduced stroke in at-risk patients with a type of atrial fibrillation that can only be detected by a pacemaker or other implanted cardiac electronic device.
Product Description
Apixaban is a synthetic small molecule pharmaceutical compound belonging to the class of direct oral anticoagulants known as factor Xa inhibitors. It is manufactured as a fine crystalline powder that is subsequently formulated into oral tablet dosage forms for clinical administration. Chemically, the molecule is a complex heterocyclic organic compound designed for high selectivity toward its biological target. It works by selectively and reversibly inhibiting activated factor Xa, an enzyme central to the blood coagulation cascade. This inhibition reduces the generation of thrombin, thereby limiting the formation of blood clots within the vascular system. Its production involves a multi-step organic synthesis process starting from specialized chemical intermediates, followed by rigorous purification to achieve pharmaceutical grade purity.
Report Coverage
| Key Attributes | Details |
|---|---|
| Product Name | Apixaban |
| Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Apixaban Price Analysis, and Segment-Wise Assessment. |
| Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
| Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
| Information Covered for Key Suppliers |
|
| Customization Scope | The report can be customized as per the requirements of the customer |
| Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
| Post-Sale Analyst Support | 360-degree analyst support after report delivery |
| Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s report presents a detailed analysis of apixaban pricing, covering global and regional trends, spot prices at key ports, and a breakdown of FOB and CIF prices.
- The study examines factors affecting apixaban price trend, including input costs, supply-demand shifts, and geopolitical impacts, offering insights for informed decision-making.
- The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
- IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The apixaban price charts ensure our clients remain at the forefront of the industry.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Request Customization
Inquire Before Buying
Speak to an Analyst
Request Brochure
Benefits of Customization
- Personalize this research
- Triangulate with your data
- Get data as per your format and definition
- Gain a deeper dive into a specific application, geography, customer, or competitor
- Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-201-971-6302
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-714-6104
Email: [email protected]
Client Testimonials
.webp)
.webp){kind=logo}
Related Reports
Why Choose Us
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
Robust Methodologies & Extensive Resources
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Subscription-Based Databases
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Primary Research-Driven Insights
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
Extensive Secondary Research
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.